Across 3 studies (all of which are review papers), all reported beneficial effects, with effect sizes ranging from small to moderate (predominantly moderate). The evidence base consists entirely of reviews rather than primary interventional trials, and no dose, duration, form, or population data were reported in the included studies. None of the studies provided statistical significance data, and study durations were not consistently reported.
Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. All studies are review articles (not primary clinical trials), which limits causal inference. No studies reported doses, durations, forms, or population segments, making it impossible to identify specific effective conditions. None of the included studies reported statistical significance, so the magnitude of benefit cannot be quantified. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed).
Bifidobacterium animalis subsp. lactis BB-12 has been associated with beneficial outcomes in various pathological and physiological conditions.
The review paper ... providing a foundation for future research aimed at optimizing the use of these technologies in clinical and industrial settings.
Bifidobacteria contribute to poultry health by modulating the gut microbiota, improving intestinal morphology and digestive enzyme activity, and regulating immune responses through cytokine balance and epithelial barrier reinforcement.